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Figure 1. Time to mortality
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2 infections, p¼0.0001). Infection incidence was signiﬁ-
cantly increased in patients receiving ATG compared to
those not receiving ATG (median 3 vs. 2, p¼0.0003). The
relative increase in infections with ATG was more pro-
nounced in RIC (+ATG median 3 vs eATG median 1) than in
MAC (+ATG median 4 vs. eATG median 3). In both RIC and
MAC, ATG use was associated with increased numbers of
CMV (112 vs. 61), HHV6 (47 vs. 13), and HSV (32 vs. 8)
infections. The relative increase in infection incidence for
+ATG patients in RIC (CMV 2.5-fold, HHV6 10.5-fold, HSV
6.5-fold increase) was greater than the increase seen for
+ATG patients in MAC (CMV 1.46-fold, HHV6 2.36-fold, HSV
3.17-fold increase).
Similar rates of severe (grade 3-4) aGVHD were observed
in +ATG patients compared to eATG patients (17.5% vs.
14.95%, p¼0.72) through day 180, indicating a potential
protective effect of ATG in unrelated/mismatched trans-
plants. In RIC, a nonsigniﬁcantly greater proportion of +ATG
patients developed severe aGVHD (19.4%) compared toeATG
patients (12.9%).
The rates of relapse/death were not different between
ATG groups (29.91% for eATG and 39.68% for +ATG), and
groups had similar mean times to relapse (148 days foreATG
and 138 days for +ATG). At 180 days, survival was 83.2% for
eATG and 71.4% for +ATG (p¼0.0426).
Conclusion: Our study demonstrates that ATG use in-
creases infection rates in alloHCT patients, with greater
impact in the RIC setting. Although relapse rates were
similar between groups, the 180-day mortality for +ATG
was signiﬁcantly greater than eATG, suggesting that in-
fectious complications may impact mortality associated
with ATG.Figure 2. Time to relapse126
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Background: Current literature supports the use of he-
matopoietic stem cell transplants (hSCT) over salvage
chemotherapy for patients with lymphoma who have
recurrent disease or are at high risk of relapse. Few studies
have been published directly comparing preparative regi-
mens, thus most institutions select regimens based on
associated toxicities. At our institution, Busulfan/Cyclo-
phosphamide (Bu-Cy) was historically used as the prepar-
ative regimen for patients with lymphoma. A transition was
made in 2009 to favor the theoretically less toxic Carmus-
tine/Etoposide/Cyclophosphamide (CBV) regimen for older
patients.
Objective: Compare the tolerability and efﬁcacy of Bu-Cy and
CBV as they pertain to autologous stem cell transplants in
older patients.
Methods: We report a retrospective review of institutional
data evaluating the safety and efﬁcacy of Bu-Cy and CBV in
patients with lymphoma receiving an autologous hSCT be-
tween January 2005 and January 2014. Patients were
excluded if they were less than 60 years of age. The primary
outcomewas the incidence of grade 3 and 4 toxicities per theCTCAE v4.03. Secondary outcomes included progression-free
and overall survival.
Results: Seventy-ﬁve patients were available for analysis,
23 received Bu-Cy and 52 received CBV. Patients who
received Bu-Cy experienced an average of 1.6 severe or life-
threatening toxicities per patient compared with 1.7 for
those who received CBV. There was no difference in pro-
gression-free (BuCy 86% vs CBV 95%) or overall survival
(BuCy 96% vs CBV 94%) at 60 days; however, there was a
trend toward increased progression-free survival (BuCy31%
vs CBV 68%) at three years Figure 1) and this trend was
supported by the increased time to relapse (BuCy 22.7 vs
CBV 61.2 months) (Figure 2).
Conclusions: This review demonstrates no difference in
terms of tolerability or efﬁcacy between Bu-Cy and CBV;
however, there is a trend towards improved relapse free
survival with CBV. Future studies are needed to compare
other utilized preparative regimens.127
Dose-Escalated G-CSF Dose Not Improve Resolution of
Neutropenia Compared to Standard-Dose G-CSF
Following Autologous Stem Cell Transplantation
Steven Triﬁlio 1, Jessica l Fong 1, Cindy Zhao 1, Junyu Zhang 1,
Derek Liu 1, Marcelo Villa 2, Jayesh Mehta 3. 1 Northwestern
Memorial Hospital, Chicago, IL; 2 Cell Therapy Processing
Facility, Northwestern Memorial Hospital, Chicago, IL;
Abstracts / Biol Blood Marrow Transplant 21 (2015) S114eS126 S1233Hematology/Oncology, Northwestern University Feinberg
School of Medicine, Chicago, IL
Granulocyte colony stimulating factors (G-CSF, Filgrastim,
Neupogen) are routinely used after autologous HSCT to
reduce the duration of severe neutropenia. Clinical studies
have not directly compared the effects of different G-CSF
doses on engraftment, thus the optimal G-CSF dose remains
unknown. A clinical initiative of dose-escalated GCSF was
instituted at NMH to determine if the duration of neu-
tropenia could be reducedwith increased G-CSF dose. Herein
are the results of an observational study comparing standard
dose to dose-escalated G-CSF for resolution of neutropenia
following auto-HSCT.
NMH electronic database was used to identify consecu-
tive autologous HSCT recipients treated at Northwestern
Memorial Hospital between 2008-9 (single daily dose Fil-
grastim 5mcg/kg) and 2010-11 (twice daily dose of Fil-
grastim-total dose¼10mcg/kg/day). All patients started G-
CSF 5 days after stem cell infusion. Resolution of neutropenia
was deﬁned as the 1st day ANC > 500cells/ml. Most patients
received a minimum of 5mcg/kg/dose total body weight
rounded up to the nearest vial size.
172 single-dose and 162 twice daily dose auto-HSCT re-
cipients were included in this study. There was no statistical
difference between study arms for age, weight, gender,
diagnosis, or G-CSF dose, the number of patients who
received a 480mcg doses of G-CSF. The number of CD34+
stem cells infused was signiﬁcantly higher in the twice daily
study arm.
Table 2 shows study results. Time to engraftment and the
number of treatment days needed to reach engraftment was
the same for both study arms. No differencewas observed for
length of stay or hospital mortality. A trend towards higher
microbiologically conﬁrmed infections was seen.
In this study, a single 5mcg/kg G-CSF dosewas as effective
as twice daily 5mcg/kg G-CSF doses for accelerating stem cell
engraftment. A randomized prospective study is needed to
conﬁrm these results.Table 1
Single vs Twice Daily G-CSF
Demographics Single Daily
Dose
Twice Daily
Dose
P-value
Number 172 163
Age (range) 56 (22-77) 57 (24-77) 0.4343
Weight (median/kg) 82.77 85.43 0.2228
G-CSF dose (mcg/kg) 148 (86) 1622 0.4955
Male 101 (59) 120 (66) 0.8711
Diagnosis
Myeloma 135 (78) 136 (75) 0.3787
NHL 24 (14) 24 (13) 0.877
Other 13 (8) 22 (12) 0.2199
CD34 cells infused
(mean-mil/kg)
6.03 6.72 0.0395
Table 2
Results
Single Twice daily P-value
Time to engraftment (days) 12 (9-27) 11 (9-24) 0.9126
Length of stay (range) 16 (7-45) 16 (9-115) 0.4777
Number of patients with
microbiologically conﬁrmed
infection
26 42 0.0787
Hospital mortality 3 (1.7) 4 (2.2) 0 99TRANSPLANT NURSING CLINICAL
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Hematopoietic stem cell transplantation (HSCT) is a treat-
ment option for many children with childhood cancers and
nonmalignant diseases. Providing both the physical and
emotional care to their child at home, parents are
frequently overwhelmed and experience signiﬁcant stress
following discharge from the hospital. Usual support often
includes home care services, written discharge informa-
tion, outpatient clinic visits and ongoing phone commu-
nication with clinicians. Traditional support groups are not
utilized since parents are often reluctant to leave their
child and may need to travel great distances to attend
meetings.
Parent telephone support groups (TSG) using group
conference calls have been successfully piloted. During the
project development phase, three eight week TSG were held.
A total of 24 parents were asked to join a group. Based on the
overwhelming positive response by both parents and health
care team, a research study formally evaluated the effec-
tiveness of the parent TSG.
Methods, Intervention, & Analysis: Two additional eight-
week TSG sessions were conducted with 16 parent par-
ticipants. Each one-hour session was audio-recorded and
later analyzed for content and themes. Sessions was
co-facilitated by the transplant clinical nurse specialist and
social worker with occasional guest presenters. A
maximum of eight parents participated in the weekly TSG
for each session. Data were analyzed for each of the eight-
week sessions and compared between groups for content
and themes.
Findings & Interpretation: A wide-range of discussion
topics included; isolation, medication administration/
adherence, nutrition, interpreting tests/labs, adjusting to
life at home, self-care and caregiver challenges. Four main
themes were identiﬁed including caregiver and family is-
sues, skill development and following guidelines/rules.
Recurrent topics focused on ongoing fear, isolation, over-
whelming stress, fatigue and sleep deprivation with global
issues of self-efﬁcacy and accommodation-adaptation
emerging.
Discussion & Implications: The telephone support groups
provided the emotional and educational support that par-
ents needed following discharge. Issues were openly dis-
cussed in a supportive structured format. This innovative
approach of ongoing support to parents facilitated prob-
lem-solving, anticipatory guidance and processing of ex-
periences and feelings. Based on this evidence based
research, there is a need to promote telephone support
groups which can lead to improved symptom management
and better parental support during this difﬁcult period
post transplant.
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